高密度野生型 IL-2 纳米颗粒优先增强 CD8⁺ T 细胞扩增并重编程肿瘤微环境

UNLABELLED: Low response rates to immune checkpoint inhibitors (ICIs) in solid tumors are often driven by insufficient tumor-infiltrating CD8⁺ T cells and immunosuppressive tumor microenvironment (TME). Although interleukin-2 (IL-2) potently expands and activates CD8⁺ T cells, its clinical use is limited by rapid clearance, dose-limiting toxicity, and regulatory T cell (T reg ) stimulation. Engineered IL-2 variants have not yet achieved meaningful clinical efficacy.

Here, polymer-modified mesoporous silica nanoparticles displaying dense, unmodified wild-type IL-2 on their surface (IL2-NP) are developed, conferring proteolytic stability and tumor retention. IL2-NP enables avidity-mediated CD8⁺ T cell binding and enhances proliferation and effector function without increased T reg binding or proliferation. Intratumoral IL2-NP expands CD8⁺ T cells, increases CD8⁺/T reg ratios, and reprograms TME through dendritic cell activation and M1-like macrophage polarization.

IL2-NP induces regression of both treated and untreated distant colorectal tumors in a CD8⁺ T cell-dependent manner. IL2-NP synergizes with ICIs and leads to complete tumor regression and immunological memory that protect against rechallenge. Treatment is well tolerated, with strong efficacy also observed in triple-negative breast and metastatic ovarian cancer models.

Overall, intratumoral IL2-NP elicits robust systemic antitumor immunity, offering a promising strategy to enhance ICIs, cancer vaccines, and adoptive T-cell therapies. GRAPHICAL ABSTRACT: This work introduces a nanoparticle platform that overcomes major shortcomings of IL-2 immunotherapy by presenting wild-type IL-2 at high density on the nanoparticle surface, thereby increasing binding avidity to effector T cells.

The resulting IL-2 nanoparticles enhance cytotoxic T cell expansion, reprogram the tumor microenvironment, and augment responses to immune checkpoint blockade to achieve robust ant-tumor immune response in mouse tumor models.